Sign in
Taking people in AustriaPhase 4

Steroid timing and blood sugar in adults with ANCA vasculitis

Tests whether splitting steroid doses across the day changes blood sugar in adults with vasculitis.

Key facts

Who runs it
Medical University Of Graz
Where
Graz, AustriaSee the site
Registry title
EFFECT OF ONCE VS TWICE DAILY ADMINISTRATION OF CORTICOSTEROIDS ON BLOOD GLUCOSE IN PATIENTS WITH ANCA-VASCULITIS MEASURED BY CONTINUOUS BLOOD GLUCOSE MONITORING - A PILOT STUDY
Status
Recruiting
Phase
Phase 4
People taking part
10 people, planned
Started
25 Sept 2020
Planned end
31 Dec 2024
Type of study
Interventional
Record updated
18 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-80 with newly diagnosed ANCA-associated vasculitis or a relapse, who take a high prednisolone dose and will wear a glucose sensor.

Age
18-80 years at the time of biopsy
Sex
Men and women
Disease stage
New diagnosis of ANCA-associated vasculitis, or a relapse of known ANCA vasculitis
Earlier treatment
A prednisolone dose of 1mg/kg body weight at the time of inclusion

Main reasons for not taking part

  • Known diabetes mellitus
  • Women who can have children and are pregnant, breastfeeding, wish to become pregnant or do not use adequate contraception
  • Skin changes that prevent placing a glucose sensor
  • Taking part in another clinical trial that could affect the results
  • Unable to follow study procedures or understand the consent form

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Written agreement to participate in the study after detailed explanation of the study
  • Male or female patients
  • New diagnosis of ANCA-associated vasculitis or a relapse of a known ANCA vasculitis
  • Age: ≥18-80 years at the time of biopsy
  • Aprednislon dose of 1mg/kg body weight at the time of inclusion
  • Wants to wear a CGM system for the duration of the study and to receive insulin therapy as needed

Who cannot take part

  • Known diabetes mellitus
  • Relevant acute or chronic disease that, in the investigator's estimation, could affect the patient's safety or affect the study results
  • Skin changes or concomitant circumstances that prevent the placement of a glucose sensor in the examiner's assessment (e.g. scar tissue)
  • Women capable of giving birth who are pregnant, breastfeeding, wish to become pregnant or do not use adequate contraception
  • Current participation in another clinical trial that would affect study results
  • Patient's inability to follow study procedures as required
  • Inability of the patient to understand the consent form

Where in Austria

  • Medical University of GrazGraz, AustriaTaking people

About the trial

What the trial wants to find out

Evaluation of whether splitting the cortisone dose to a twice daily dose leads to increased time in the glucose target range.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
EFFECT OF ONCE VS TWICE DAILY ADMINISTRATION OF CORTICOSTEROIDS ON BLOOD GLUCOSE IN PATIENTS WITH ANCA-VASCULITIS MEASURED BY CONTINUOUS BLOOD GLUCOSE MONITORING - A PILOT STUDY
Plain-language title
Steroid timing and blood sugar in adults with ANCA vasculitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
18 November 2024